Eli Lilly and stock is trading -6.56% below its average target price of $908.48 after dropping -6.3% during today's morning session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $600.0 to $1100.0 per share.
Eli Lilly and's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 0.8%. The stock's short ratio is 2.23. The company's insiders own 0.15% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 83.7%. In conclusion, we believe there is mixed market sentiment regarding Eli Lilly and.
Institutions Invested in Eli Lilly and
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | Lilly Endowment, Inc | 10% | 97,367,369 | $82,655,161,921 |
| 2024-03-31 | Vanguard Group Inc | 8% | 72,745,011 | $61,753,241,613 |
| 2024-03-31 | Blackrock Inc. | 7% | 65,274,385 | $55,411,427,020 |
| 2024-03-31 | PNC Financial Services Group, Inc. | 5% | 51,438,196 | $43,665,885,840 |
| 2024-03-31 | State Street Corporation | 4% | 34,258,566 | $29,082,097,513 |
| 2024-03-31 | FMR, LLC | 4% | 34,082,478 | $28,932,616,406 |
| 2024-03-31 | Capital World Investors | 3% | 24,536,055 | $20,828,657,688 |
| 2024-03-31 | Primecap Management Company | 2% | 21,254,190 | $18,042,682,409 |
| 2024-03-31 | Price (T.Rowe) Associates Inc | 2% | 20,613,061 | $17,498,427,986 |
| 2024-03-31 | JP Morgan Chase & Company | 2% | 19,202,963 | $16,301,395,759 |
